877PFirst-line (1L) or second-line (2L) avelumab monotherapy in patients (pts) with advanced renal cell carcinoma (aRCC) enrolled in the phase Ib JAVELIN solid tumor trial

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Annals of oncology 2018-10, Vol.29 (suppl_8)
Hauptverfasser:	Vaishampayan, U N, Schöffski, P, Ravaud, A, Borel, C, Song, T, Guenther, S, Grewal, J, Gulley, J
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

container_end_page
container_issue	suppl_8
container_start_page
container_title	Annals of oncology
container_volume	29
creator	Vaishampayan, U N Schöffski, P Ravaud, A Borel, C Song, T Guenther, S Grewal, J Gulley, J
description
doi_str_mv	10.1093/annonc/mdy283.086
format	Article
fullrecord	<record><control><sourceid>oup</sourceid><recordid>TN_cdi_oup_primary_10_1093_annonc_mdy283_086</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/annonc/mdy283.086</oup_id><sourcerecordid>10.1093/annonc/mdy283.086</sourcerecordid><originalsourceid>FETCH-oup_primary_10_1093_annonc_mdy283_0863</originalsourceid><addsrcrecordid>eNqVkN1KwzAcxYMoWD8ewLv_ZQd2S9qtH5dSNpwMERFvy39tpJE0CUk66TP5kotsL-DNOXA4HA4_Qh4YnTNaZQtUSqt2MXRTWmZzWuYXJGKrvEpKumSXJKJVmiXFKltekxvnvimleZVWEfkti-JtI6zziRSKQ8x2M9AWHG-16s5ZGjI8cDkOuIdBK-17btFMIBQY9IIr7yA23s3gR_gesDugankHliuU0HIZBG0rlB4QYnyv6xlwZbWUoRRGwh6YHh2H7R5enj7Xu-0rOC1FB34cwh1vBco7cvWF0vH7s9-Sx836o35O9GgaY8WAdmoYbf6ANCcgzQlIE4Bk_6wfAaYwav8</addsrcrecordid><sourcetype>Publisher</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>877PFirst-line (1L) or second-line (2L) avelumab monotherapy in patients (pts) with advanced renal cell carcinoma (aRCC) enrolled in the phase Ib JAVELIN solid tumor trial</title><source>Electronic Journals Library</source><source>Alma/SFX Local Collection</source><creator>Vaishampayan, U N ; Schöffski, P ; Ravaud, A ; Borel, C ; Song, T ; Guenther, S ; Grewal, J ; Gulley, J</creator><creatorcontrib>Vaishampayan, U N ; Schöffski, P ; Ravaud, A ; Borel, C ; Song, T ; Guenther, S ; Grewal, J ; Gulley, J</creatorcontrib><identifier>ISSN: 0923-7534</identifier><identifier>EISSN: 1569-8041</identifier><identifier>DOI: 10.1093/annonc/mdy283.086</identifier><language>eng</language><publisher>Oxford University Press</publisher><ispartof>Annals of oncology, 2018-10, Vol.29 (suppl_8)</ispartof><rights>The Author(s) 2018. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com. 2018</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids></links><search><creatorcontrib>Vaishampayan, U N</creatorcontrib><creatorcontrib>Schöffski, P</creatorcontrib><creatorcontrib>Ravaud, A</creatorcontrib><creatorcontrib>Borel, C</creatorcontrib><creatorcontrib>Song, T</creatorcontrib><creatorcontrib>Guenther, S</creatorcontrib><creatorcontrib>Grewal, J</creatorcontrib><creatorcontrib>Gulley, J</creatorcontrib><title>877PFirst-line (1L) or second-line (2L) avelumab monotherapy in patients (pts) with advanced renal cell carcinoma (aRCC) enrolled in the phase Ib JAVELIN solid tumor trial</title><title>Annals of oncology</title><issn>0923-7534</issn><issn>1569-8041</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid/><recordid>eNqVkN1KwzAcxYMoWD8ewLv_ZQd2S9qtH5dSNpwMERFvy39tpJE0CUk66TP5kotsL-DNOXA4HA4_Qh4YnTNaZQtUSqt2MXRTWmZzWuYXJGKrvEpKumSXJKJVmiXFKltekxvnvimleZVWEfkti-JtI6zziRSKQ8x2M9AWHG-16s5ZGjI8cDkOuIdBK-17btFMIBQY9IIr7yA23s3gR_gesDugankHliuU0HIZBG0rlB4QYnyv6xlwZbWUoRRGwh6YHh2H7R5enj7Xu-0rOC1FB34cwh1vBco7cvWF0vH7s9-Sx836o35O9GgaY8WAdmoYbf6ANCcgzQlIE4Bk_6wfAaYwav8</recordid><startdate>20181001</startdate><enddate>20181001</enddate><creator>Vaishampayan, U N</creator><creator>Schöffski, P</creator><creator>Ravaud, A</creator><creator>Borel, C</creator><creator>Song, T</creator><creator>Guenther, S</creator><creator>Grewal, J</creator><creator>Gulley, J</creator><general>Oxford University Press</general><scope/></search><sort><creationdate>20181001</creationdate><title>877PFirst-line (1L) or second-line (2L) avelumab monotherapy in patients (pts) with advanced renal cell carcinoma (aRCC) enrolled in the phase Ib JAVELIN solid tumor trial</title><author>Vaishampayan, U N ; Schöffski, P ; Ravaud, A ; Borel, C ; Song, T ; Guenther, S ; Grewal, J ; Gulley, J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-oup_primary_10_1093_annonc_mdy283_0863</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Vaishampayan, U N</creatorcontrib><creatorcontrib>Schöffski, P</creatorcontrib><creatorcontrib>Ravaud, A</creatorcontrib><creatorcontrib>Borel, C</creatorcontrib><creatorcontrib>Song, T</creatorcontrib><creatorcontrib>Guenther, S</creatorcontrib><creatorcontrib>Grewal, J</creatorcontrib><creatorcontrib>Gulley, J</creatorcontrib><jtitle>Annals of oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Vaishampayan, U N</au><au>Schöffski, P</au><au>Ravaud, A</au><au>Borel, C</au><au>Song, T</au><au>Guenther, S</au><au>Grewal, J</au><au>Gulley, J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>877PFirst-line (1L) or second-line (2L) avelumab monotherapy in patients (pts) with advanced renal cell carcinoma (aRCC) enrolled in the phase Ib JAVELIN solid tumor trial</atitle><jtitle>Annals of oncology</jtitle><date>2018-10-01</date><risdate>2018</risdate><volume>29</volume><issue>suppl_8</issue><issn>0923-7534</issn><eissn>1569-8041</eissn><pub>Oxford University Press</pub><doi>10.1093/annonc/mdy283.086</doi></addata></record>
fulltext	fulltext
identifier	ISSN: 0923-7534
ispartof	Annals of oncology, 2018-10, Vol.29 (suppl_8)
issn	0923-7534 1569-8041
language	eng
recordid	cdi_oup_primary_10_1093_annonc_mdy283_086
source	Electronic Journals Library; Alma/SFX Local Collection
title	877PFirst-line (1L) or second-line (2L) avelumab monotherapy in patients (pts) with advanced renal cell carcinoma (aRCC) enrolled in the phase Ib JAVELIN solid tumor trial
url	https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-29T09%3A42%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-oup&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=877PFirst-line%20(1L)%20or%20second-line%20(2L)%20avelumab%20monotherapy%20in%20patients%20(pts)%20with%20advanced%20renal%20cell%20carcinoma%20(aRCC)%20enrolled%20in%20the%20phase%20Ib%20JAVELIN%20solid%20tumor%20trial&rft.jtitle=Annals%20of%20oncology&rft.au=Vaishampayan,%20U%20N&rft.date=2018-10-01&rft.volume=29&rft.issue=suppl_8&rft.issn=0923-7534&rft.eissn=1569-8041&rft_id=info:doi/10.1093/annonc/mdy283.086&rft_dat=%3Coup%3E10.1093/annonc/mdy283.086%3C/oup%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rft_oup_id=10.1093/annonc/mdy283.086&rfr_iscdi=true